Literature DB >> 16055622

Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

J J Soler-Cataluña1, M A Martínez-García, P Román Sánchez, E Salcedo, M Navarro, R Ochando.   

Abstract

BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) often present with severe acute exacerbations requiring hospital treatment. However, little is known about the prognostic consequences of these exacerbations. A study was undertaken to investigate whether severe acute exacerbations of COPD exert a direct effect on mortality.
METHODS: Multivariate techniques were used to analyse the prognostic influence of acute exacerbations of COPD treated in hospital (visits to the emergency service and admissions), patient age, smoking, body mass index, co-morbidity, long term oxygen therapy, forced spirometric parameters, and arterial blood gas tensions in a prospective cohort of 304 men with COPD followed up for 5 years. The mean (SD) age of the patients was 71 (9) years and forced expiratory volume in 1 second was 46 (17)%.
RESULTS: Only older age (hazard ratio (HR) 5.28, 95% CI 1.75 to 15.93), arterial carbon dioxide tension (HR 1.07, 95% CI 1.02 to 1.12), and acute exacerbations of COPD were found to be independent indicators of a poor prognosis. The patients with the greatest mortality risk were those with three or more acute COPD exacerbations (HR 4.13, 95% CI 1.80 to 9.41).
CONCLUSIONS: This study shows for the first time that severe acute exacerbations of COPD have an independent negative impact on patient prognosis. Mortality increases with the frequency of severe exacerbations, particularly if these require admission to hospital.

Entities:  

Mesh:

Year:  2005        PMID: 16055622      PMCID: PMC1747235          DOI: 10.1136/thx.2005.040527

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  35 in total

1.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

2.  Prognostic value of nutritional status in chronic obstructive pulmonary disease.

Authors:  C Landbo; E Prescott; P Lange; J Vestbo; T P Almdal
Journal:  Am J Respir Crit Care Med       Date:  1999-12       Impact factor: 21.405

3.  Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments)

Authors:  A F Connors; N V Dawson; C Thomas; F E Harrell; N Desbiens; W J Fulkerson; P Kussin; P Bellamy; L Goldman; W A Knaus
Journal:  Am J Respir Crit Care Med       Date:  1996-10       Impact factor: 21.405

4.  The radiologic manifestations of Legionnaire's disease. The Ohio Community-Based Pneumonia Incidence Study Group.

Authors:  M J Tan; J S Tan; R H Hamor; T M File; R F Breiman
Journal:  Chest       Date:  2000-02       Impact factor: 9.410

5.  Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study.

Authors:  P D Scanlon; J E Connett; L A Waller; M D Altose; W C Bailey; A S Buist; D P Tashkin
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

6.  Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study.

Authors:  R E Kanner; N R Anthonisen; J E Connett
Journal:  Am J Respir Crit Care Med       Date:  2001-08-01       Impact factor: 21.405

7.  [The impact of COPD on hospital resources: the specific burden of COPD patients with high rates of hospitalization].

Authors:  J Soler; L Sánchez; M Latorre; J Alamar; P Román; M Perpiñá
Journal:  Arch Bronconeumol       Date:  2001-10       Impact factor: 4.872

8.  Pharmacoeconomic evaluation of COPD.

Authors:  D E Hilleman; N Dewan; M Malesker; M Friedman
Journal:  Chest       Date:  2000-11       Impact factor: 9.410

9.  Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure.

Authors:  M Oswald-Mammosser; E Weitzenblum; E Quoix; G Moser; A Chaouat; C Charpentier; R Kessler
Journal:  Chest       Date:  1995-05       Impact factor: 9.410

10.  Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease.

Authors:  M G Seneff; D P Wagner; R P Wagner; J E Zimmerman; W A Knaus
Journal:  JAMA       Date:  1995-12-20       Impact factor: 56.272

View more
  544 in total

1.  Comparison of clinico-physiologic and CT imaging risk factors for COPD exacerbation.

Authors:  Jung-Wan Yoo; Yoonki Hong; Joon Beom Seo; Eun Jin Chae; Seung Won Ra; Ji-Hyun Lee; Eun Kyung Kim; Seunghee Baek; Tae-Hyung Kim; Woo Jin Kim; Jin Hwa Lee; Sang-Min Lee; Sangyeub Lee; Seong Yong Lim; Tae Rim Shin; Ho Il Yoon; Seung Soo Sheen; Jae Seung Lee; Jin Won Huh; Yeon-Mok Oh; Sang-Do Lee
Journal:  J Korean Med Sci       Date:  2011-11-29       Impact factor: 2.153

2.  Chronic obstructive pulmonary disease exacerbations: accurate and easy measurement promises much.

Authors:  Stephen I Rennard; Kristina L Bailey
Journal:  Am J Respir Crit Care Med       Date:  2012-06-01       Impact factor: 21.405

Review 3.  [Treatment of not-with cystic fibrosis associated forms bronchiectasis (non-CF bronchiectasis)].

Authors:  J Rademacher; M W Pletz; T Welte
Journal:  Internist (Berl)       Date:  2010-12       Impact factor: 0.743

4.  Machine Learning and Prediction of All-Cause Mortality in COPD.

Authors:  Matthew Moll; Dandi Qiao; Elizabeth A Regan; Gary M Hunninghake; Barry J Make; Ruth Tal-Singer; Michael J McGeachie; Peter J Castaldi; Raul San Jose Estepar; George R Washko; James M Wells; David LaFon; Matthew Strand; Russell P Bowler; MeiLan K Han; Jorgen Vestbo; Bartolome Celli; Peter Calverley; James Crapo; Edwin K Silverman; Brian D Hobbs; Michael H Cho
Journal:  Chest       Date:  2020-04-27       Impact factor: 9.410

Review 5.  Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.

Authors:  K Suresh Babu; Jack A Kastelik; Jaymin B Morjaria
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

6.  Collateral damage: depressive symptoms in the partners of COPD patients.

Authors:  Andriana I Papaioannou; Stamatoula Tsikrika; Konstantinos Bartziokas; Foteini Karakontaki; Emmanouil Kastanakis; Filia Diamantea; Aikaterini Haniotou; Spyros Papiris; Vlassis Polychronopoulos; Stelios Loukides; Konstantinos Kostikas
Journal:  Lung       Date:  2014-05-11       Impact factor: 2.584

7.  Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.

Authors:  Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; V N Maturu; Sahajal Dhooria; K T Prasad; Inderpaul S Sehgal; Lakshmikant B Yenge; Aditya Jindal; Navneet Singh; A G Ghoshal; G C Khilnani; J K Samaria; S N Gaur; D Behera
Journal:  Lung India       Date:  2013-07

8.  Evolution of the COPD Assessment Test score during chronic obstructive pulmonary disease exacerbations: determinants and prognostic value.

Authors:  Darwin Feliz-Rodriguez; Santiago Zudaire; Carlos Carpio; Elizabet Martínez; Antonia Gómez-Mendieta; Ana Santiago; Rodolfo Alvarez-Sala; Francisco García-Río
Journal:  Can Respir J       Date:  2013 Sep-Oct       Impact factor: 2.409

9.  Associations with chest illness and mortality in chronic spinal cord injury.

Authors:  Valery A Danilack; Kelly L Stolzmann; David R Gagnon; Robert Brown; Carlos G Tun; Leslie R Morse; Eric Garshick
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

10.  Integrated interdisciplinary care for patients with chronic obstructive pulmonary disease reduces emergency department visits, admissions and costs: a quality assurance study.

Authors:  Esther Dajczman; Chantal Robitaille; Pierre Ernst; Andrew Michael Hirsch; Norman Wolkove; David Small; Judy Bianco; Hartley Stern; Mark Palayew
Journal:  Can Respir J       Date:  2013 Sep-Oct       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.